Product Description
Sodium polystyrene sulfonate is used to treat high levels of potassium in the blood, also called hyperkalemia. (Sourced from: https://www.mayoclinic.org/drugs-supplements/sodium-polystyrene-sulfonate-oral-route-route-not-applicable/description/drg-20073487)
Mechanisms of Action: Potassium Reducer
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Brazil | Chile | Colombia | Dominican Republic | Egypt | France | Germany | Hong Kong | India | Ireland | Italy | Malaysia | Morocco | New Zealand | Pakistan | Taiwan | Tunisia | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Hyperkalemia
Known Adverse Events: Colitis | Colitis, Ischemic | Fecal Impaction | Anorexia | Constipation | Diarrhea | Bezoars
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|